Reshetnyak Andrey V, Murray Phillip B, Shi Xiarong, Mo Elizabeth S, Mohanty Jyotidarsini, Tome Francisco, Bai Hanwen, Gunel Murat, Lax Irit, Schlessinger Joseph
Department of Pharmacology, Yale School of Medicine, New Haven, CT 06520;
Department of Neurosurgery, Yale School of Medicine, New Haven, CT 06520.
Proc Natl Acad Sci U S A. 2015 Dec 29;112(52):15862-7. doi: 10.1073/pnas.1520099112. Epub 2015 Nov 16.
Receptor tyrosine kinases (RTKs) are a class of cell surface receptors that, upon ligand binding, stimulate a variety of critical cellular functions. The orphan receptor anaplastic lymphoma kinase (ALK) is one of very few RTKs that remain without a firmly established protein ligand. Here we present a novel cytokine, FAM150B, which we propose naming augmentor-α (AUG-α), as a ligand for ALK. AUG-α binds ALK with high affinity and activates ALK in cells with subnanomolar potency. Detailed binding experiments using cells expressing ALK or the related receptor leukocyte tyrosine kinase (LTK) demonstrate that AUG-α binds and robustly activates both ALK and LTK. We show that the previously established LTK ligand FAM150A (AUG-β) is specific for LTK and only weakly binds to ALK. Furthermore, expression of AUG-α stimulates transformation of NIH/3T3 cells expressing ALK, induces IL-3 independent growth of Ba/F3 cells expressing ALK, and is expressed in neuroblastoma, a cancer partly driven by ALK. These experiments reveal the hierarchy and specificity of two cytokines as ligands for ALK and LTK and set the stage for elucidating their roles in development and disease states.
受体酪氨酸激酶(RTKs)是一类细胞表面受体,在配体结合后,可刺激多种关键的细胞功能。孤儿受体间变性淋巴瘤激酶(ALK)是极少数尚未有明确蛋白配体的RTKs之一。在此,我们提出一种新型细胞因子FAM150B,我们建议将其命名为增强因子-α(AUG-α),作为ALK的配体。AUG-α以高亲和力结合ALK,并在细胞中以亚纳摩尔效力激活ALK。使用表达ALK或相关受体白细胞酪氨酸激酶(LTK)的细胞进行的详细结合实验表明,AUG-α能结合并强烈激活ALK和LTK。我们发现,先前确定的LTK配体FAM150A(AUG-β)对LTK具有特异性,仅与ALK弱结合。此外,AUG-α的表达可刺激表达ALK的NIH/3T3细胞发生转化,诱导表达ALK的Ba/F3细胞在无白细胞介素-3的情况下生长,并且在神经母细胞瘤中表达,神经母细胞瘤是一种部分由ALK驱动的癌症。这些实验揭示了两种细胞因子作为ALK和LTK配体的层级关系和特异性,为阐明它们在发育和疾病状态中的作用奠定了基础。